TMS

TMS
Name	Transcranial Magnetic Stimulation
Specialty	Neurology, Psychiatry, Neuroscience
Invented	1985
Inventor	Antony Barker; Robert J. Coffey; Alberto Priori

TMS

Transcranial Magnetic Stimulation is a noninvasive neuromodulation technique that uses time-varying magnetic fields to induce electric currents in focal regions of the cerebral cortex. Initially developed as an investigative tool in neurophysiology and cognitive neuroscience, it has evolved into a therapeutic modality adopted by Food and Drug Administration-cleared programs, clinical networks, and academic centers across United States, European Union, and Japan. Devices and protocols are implemented in hospitals, clinics, and research laboratories affiliated with institutions such as Massachusetts General Hospital, University College London, National Institutes of Health, and Karolinska Institute.

Overview

Transcranial Magnetic Stimulation was derived from principles of electromagnetic induction first described by Michael Faraday and adapted for neurostimulation by pioneers at Royal Hallamshire Hospital and research groups including those at University of Sheffield and Harvard Medical School. The method employs coil geometries like figure-of-eight, H-coils, and double-cone designs produced by manufacturers (for example, companies collaborating with GE Healthcare and Neuronetics). Clinical applications have been informed by trials conducted at centers such as Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital.

Medical Uses

TMS has regulatory approval and clinical adoption for treatment-resistant major depressive disorder in adults by agencies including the Food and Drug Administration and national regulatory bodies in United Kingdom and European Medicines Agency jurisdictions. It is also used off-label or investigationally for conditions studied at Stanford University, Columbia University, and University of Pennsylvania such as obsessive-compulsive disorder, post-traumatic stress disorder, chronic pain syndromes, and stroke rehabilitation. Device-specific indications have been pursued in randomized controlled trials coordinated by groups at Yale School of Medicine and Imperial College London.

Mechanism of Action

The neurophysiological basis rests on electromagnetic induction: a time-varying current through a coil generates a magnetic field that penetrates the scalp and skull, inducing an electric field in cortical tissue—an effect grounded in work by Michael Faraday and modeled using computational frameworks developed at Massachusetts Institute of Technology and University of Oxford. Induced currents can depolarize pyramidal neurons in layers II/III and V and modulate synaptic plasticity via mechanisms convergent with long-term potentiation and long-term depression described in studies from Hebb Prize-winning laboratories and groups at University of California, San Diego. Neurochemical and network-level changes have been observed using concurrent modalities such as functional magnetic resonance imaging at Wellcome Centre for Human Neuroimaging and positron emission tomography at Brookhaven National Laboratory.

Procedure and Protocols

Clinical TMS protocols specify coil placement over cortical landmarks like the left dorsolateral prefrontal cortex, often localized using neuronavigation systems developed in collaboration with teams at University of Freiburg and McGill University. Standard protocols include high-frequency (10–20 Hz) stimulation, intermittent theta-burst stimulation modeled after protocols from University of Magdeburg, and low-frequency (1 Hz) inhibitory approaches used in trials at Mount Sinai Health System. Sessions typically last 20–45 minutes over daily treatments for 4–6 weeks; accelerated and spaced protocols have been trialed in multicenter studies led by investigators at University of Toronto and Karolinska Institute.

Efficacy and Safety

Large randomized controlled trials and meta-analyses led by consortia including Cochrane Collaboration and researchers at Vanderbilt University report efficacy in treatment-resistant depression with response and remission rates varying by protocol, device, and patient selection. Safety profiles compiled by regulatory agencies and academic centers note common transient adverse events such as scalp discomfort and headache; rare but serious risks include provocation of seizures documented in case series from University of California, Los Angeles and Washington University in St. Louis. Guidelines for use and contraindications are provided by professional societies including the American Psychiatric Association and European Psychiatric Association.

History and Development

Early demonstrations of magnetic stimulation of peripheral nerves were reported in the 1970s and 1980s by groups at University of Sheffield and UCL Institute of Neurology, with the first human transcranial applications described in the mid-1980s. Key contributors include researchers affiliated with Royal Hallamshire Hospital, Hammersmith Hospital, and academic collaborators at University of Milano. Commercialization and regulatory milestones occurred through the 2000s when companies partnered with academic centers and regulatory bodies such as the Food and Drug Administration granted clearances that expanded clinical uptake.

Research and Future Directions

Ongoing research at multidisciplinary centers including Massachusetts General Hospital, University College London, Stanford University, and National Institutes of Health explores personalized targeting using functional connectivity biomarkers derived from Human Connectome Project datasets, closed-loop stimulation combining TMS with real-time electroencephalography developed at École Polytechnique Fédérale de Lausanne, and combining TMS with pharmacological agents investigated in trials sponsored by academic–industry consortia involving GlaxoSmithKline and Pfizer. Future directions include deeper stimulation technologies, home-based devices under study in partnerships with clinical networks, and integration with neuroimaging and genetic stratification efforts informed by projects like ENIGMA Consortium.

Category:Neuroscience